000			02159 a2200625 4500
005			20250515232305.0
264		0	_c20110203
008			201102s 0 0 eng d
022			_a1471-2407
024	7		_a10.1186/1471-2407-10-368 _2doi
040			_aNLM _beng _cNLM
100	1		_aJavle, Milind M
245	0	0	_aInhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies. _h[electronic resource]
260			_bBMC cancer _cJul 2010
300			_a368 p. _bdigital
500			_aPublication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAdenocarcinoma _xdrug therapy
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAntineoplastic Combined Chemotherapy Protocols
650	0	4	_aBiomarkers, Tumor _xmetabolism
650	0	4	_aErbB Receptors _xantagonists & inhibitors
650	0	4	_aErlotinib Hydrochloride
650	0	4	_aEverolimus
650	0	4	_aFemale
650	0	4	_aFluorescent Antibody Technique
650	0	4	_aHumans
650	0	4	_aImmunoenzyme Techniques
650	0	4	_aImmunosuppressive Agents _xtherapeutic use
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aNeoplasm Staging
650	0	4	_aPancreatic Neoplasms _xdrug therapy
650	0	4	_aPhosphorylation
650	0	4	_aPrognosis
650	0	4	_aProspective Studies
650	0	4	_aProtein Kinase Inhibitors _xtherapeutic use
650	0	4	_aProto-Oncogene Proteins c-akt _xmetabolism
650	0	4	_aQuinazolines _xtherapeutic use
650	0	4	_aSignal Transduction
650	0	4	_aSirolimus _xanalogs & derivatives
650	0	4	_aSurvival Rate
650	0	4	_aTOR Serine-Threonine Kinases _xantagonists & inhibitors
700	1		_aShroff, Rachna T
700	1		_aXiong, Henry
700	1		_aVaradhachary, Gauri A
700	1		_aFogelman, David
700	1		_aReddy, Shrikanth A
700	1		_aDavis, Darren
700	1		_aZhang, Yujian
700	1		_aWolff, Robert A
700	1		_aAbbruzzese, James L
773	0		_tBMC cancer _gvol. 10 _gp. 368
856	4	0	_uhttps://doi.org/10.1186/1471-2407-10-368 _zAvailable from publisher's website
999			_c19972906 _d19972906